The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 0.08 - 0.12 µg/ml. Required to yield one half maximal inhibition [ND50] of the biological activity of Rat SCF (15 ng/ml)
Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 31 kDa. Used in conjunction with compatible secondary reagents the detection limit for recombinant Rat SCF is 1.5-3.0 ng/lane, under either reducing or non reducing conditions.
Use a concentration of 0.5 - 2 µg/ml. Using 100 µl/well antibody solution, allows the detection of at least 0.2 - 0.4 ng/well of recombinant Rat SCF in conjunction with compatible secondary reagents.
Use a concentration of 0.5 - 2 µg/ml. Using 100 µl/well antibody solution, in conjunction with Biotinylated Anti-Rat SCF as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant Rat SCF.
FunctionLigand for the receptor-type protein-tyrosine kinase KIT. Plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KITLG/SCF binding can activate several signaling pathways. Promotes phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and subsequent activation of the kinase AKT1. KITLG/SCF and KIT also transmit signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. KITLG/SCF and KIT promote activation of STAT family members STAT1, STAT3 and STAT5. KITLG/SCF and KIT promote activation of PLCG1, leading to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KITLG/SCF acts synergistically with other cytokines, probably interleukins.
Involvement in diseaseHyperpigmentation with or without hypopigmentation, familial progressive Deafness, congenital, unilateral or asymmetric
Sequence similaritiesBelongs to the SCF family.
Developmental stageActs in the early stages of hematopoiesis.
Post-translational modificationsA soluble form (sKITLG) is produced by proteolytic processing of isoform 1 in the extracellular domain. Found in two differentially glycosylated forms, LMW-SCF and HMW-SCF. LMW-SCF is fully N-glycosylated at Asn-145, partially N-glycosylated at Asn-90, O-glycosylated at Ser-167, Thr-168 and Thr-180, and not glycosylated at Asn-97 or Asn-118. HMW-SCF is N-glycosylated at Asn-118, Asn-90 and Asn-145, O-glycosylated at Ser-167, Thr-168 and Thr-180, and not glycosylated at Asn-97. A soluble form exists as a cleavage product of the extracellular domain.